PURPOSE: To assess the treatment of dry eye disease (DED) with lifitegrast and clinical outcomes using real world evidence.

METHODS: Retrospective observational analysis of American Academy of Ophthalmology IRIS® (Intelligent Research in Sight) Registry electronic health records data that were linked to pharmacy claim information. Adults with a prior diagnosis of DED were indexed on first pharmacy claim for lifitegrast from Jan 1, 2017, through Sept 30, 2023 (index period). Additional criteria included ≥1 year pre-index and ≥1-year post-index pharmacy claims coverage. Endpoints analyzed will include changes from pre-index in tear film break-up time (TFBUT) and visual acuity over the study period. Results will also include study population stratifications by change in TFBUT (eg, improved; stable; improved/stable).

RESULTS: TBD

CONCLUSION: TBD